Related Experiment Videos
[Cost-effectiveness of hypertension treatment in Catalonia (Spain)]
Pedro Plans Rubió1, Ricard Tresserras Gaju, Encarna Navas Alcalá
1Servei d'Avaluació i Seguiment de Programes, Direcció General de Salut Pública, Departament de Sanitat, Barcelona, Spain.
Insights
Hydrochlorothiazide and propranolol are the most cost-effective treatments for moderate/severe hypertension, while hydrochlorothiazide and nifedipine are best for mild hypertension in Catalonia. These findings aid in optimizing hypertension pharmacotherapy decisions.
Area of Science:
- Pharmacoeconomics
- Cardiovascular Medicine
- Public Health
Context:
- Hypertension management is crucial for preventing cardiovascular events.
- Cost-effectiveness analysis of pharmacological treatments is vital for healthcare resource allocation.
- This study focuses on Catalonia, Spain, providing regional insights.
Purpose:
- To assess the cost-effectiveness of five pharmacological treatments for hypertension.
- To compare the cost per life year gained (LYG) for different drug classes.
- To identify the most cost-effective hypertension therapies for moderate/severe and mild hypertension.
Summary:
- Cost-effectiveness varied by drug and hypertension severity, measured in Spanish Pesetas per LYG.
- Hydrochlorothiazide and propranolol were most cost-effective for moderate/severe hypertension.
- Hydrochlorothiazide and nifedipine demonstrated the best cost-effectiveness for mild hypertension.
Impact:
- Provides evidence for optimizing hypertension treatment strategies in Catalonia.
- Informs healthcare providers and policymakers on cost-effective drug choices.
- Contributes to the global understanding of hypertension pharmacoeconomics.
Background:
We assessed the cost-effectiveness of pharmacological treatments for hypertension to prevent coronary heart disease and stroke in Catalonia (Spain).
Methods:
Cost-effectiveness was measured as the cost in Spanish Ptas per life year gained (LYG) in 1998 in individuals aged 40 to 69 years with moderate/severe hypertension (>= 105 mmHg) and mild hypertension (95-104 mmHg). We evaluated hydrochlorothiazide (diuretic), propranolol (-blocker), nifedipine (calcium antagonist), captopril (angiotensin-converting-enzyme inhibitor) and prazosin (*-adrenergic blocker).
Results:
Cost-effectiveness ranged from 706,100 to 446,780 ptas. per LYG in men and from 635,100 to 810,270 ptas. per LYG in women with moderate/severe hypertension and from 108,770 to 682,460 ptas. per LYG in men and from 101,000 to 12,699,000 ptas. per LYG in women with mild hypertension. Incremental cost-effectiveness analysis showed that hydrochlorothiazide and propranolol were the most cost-effective treatments in individuals with moderate/severe hypertension while hydrochlorothiazide and nifedipine were most cost-effective in those with mild hypertension.
Conclusion:
In this study, greatest-to-lowest cost-effectiveness of assessed treatments was as follows: hydrochlorohiazide, propranolol, nifedipine, prazosin and captopril in moderate/severe hypertension and hydrochlorothiazide, nifedipine, propranolol, prazosin and captopril in mild hypertension.